Loading stock data…
DMAC
$6.45+0.13 (+2.06%)
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
DiaMedica Therapeutics Inc. in the Healthcare sector is trading at $6.45. The stock is currently 38% below its 52-week high of $10.42, remaining 9.0% below its 200-day moving average. Technical signals show neutral RSI of 51 and bullish MACD crossover, explaining why DMAC maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 51) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.45
Potential Upside
5%
Whystock Fair Value$6.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus4 analysts
Mean target$15.50+140.3%
Range$11.00 – $25.00
Fundamentals
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kal...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$348.62M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.15
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-58.39%
Volume
Today's trading volume
114,978
Recent News
DiaMedica Therapeutics (NASDAQ:DMAC) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
DiaMedica Therapeutics Q1 Earnings Call Highlights
DiaMedica Therapeutics (NASDAQ:DMAC) executives outlined progress across the company’s DM199 clinical programs in preeclampsia and acute ischemic stroke during the company’s first-quarter 2026 earnings call, while also reviewing quarter-end liquidity and spending trends as development work expands g
DiaMedica Therapeutics Highlights DM199 Preeclampsia Data, Stroke Interim Catalyst at RedChip Conference
DiaMedica Therapeutics (NASDAQ:DMAC) President and CEO Rick Pauls outlined the company’s development programs for its lead candidate, DM199, during a presentation at the RedChip Biotech Investor Conference, highlighting ongoing work in preeclampsia and acute ischemic stroke as well as upcoming clini
DiaMedica Therapeutics Inc (DMAC) Q4 2025 Earnings Call Highlights: Strong Cash Position and ...
DiaMedica Therapeutics Inc (DMAC) reports robust financial health and significant advancements in its clinical trials, despite facing some enrollment and regulatory challenges.
DiaMedica Therapeutics Inc. Q4 2025 Earnings Call Summary
Moby summary of DiaMedica Therapeutics Inc.'s Q4 2025 earnings call